JP2022526364A - 炎症性障害の治療のための新規化合物及びその医薬組成物 - Google Patents

炎症性障害の治療のための新規化合物及びその医薬組成物 Download PDF

Info

Publication number
JP2022526364A
JP2022526364A JP2021557761A JP2021557761A JP2022526364A JP 2022526364 A JP2022526364 A JP 2022526364A JP 2021557761 A JP2021557761 A JP 2021557761A JP 2021557761 A JP2021557761 A JP 2021557761A JP 2022526364 A JP2022526364 A JP 2022526364A
Authority
JP
Japan
Prior art keywords
independently selected
substituted
compound
mixture
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526364A5 (https=
Inventor
マンモリティ オスカー
マリー ジャリ エレーヌ
オルスリック ミスラブ
ブルバン ディナーナ
コマク マリジャナ
クリストフ ザビエル ブリス レジナルド
アッカリ ルハリド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2022526364A publication Critical patent/JP2022526364A/ja
Publication of JP2022526364A5 publication Critical patent/JP2022526364A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021557761A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904373.6 2019-03-29
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058064 WO2020200900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526364A true JP2022526364A (ja) 2022-05-24
JP2022526364A5 JP2022526364A5 (https=) 2023-04-03

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557761A Pending JP2022526364A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (18)

Country Link
US (1) US20220218679A1 (https=)
EP (1) EP3947378B1 (https=)
JP (1) JP2022526364A (https=)
KR (1) KR20210145238A (https=)
CN (1) CN113646305A (https=)
AR (1) AR118521A1 (https=)
AU (1) AU2020252038A1 (https=)
BR (1) BR112021019055A2 (https=)
CA (1) CA3134736A1 (https=)
CO (1) CO2021014223A2 (https=)
GB (1) GB201904373D0 (https=)
IL (1) IL286677A (https=)
MA (1) MA55497A (https=)
MX (1) MX2021011576A (https=)
PH (1) PH12021552375A1 (https=)
SG (1) SG11202110644WA (https=)
TW (1) TW202102501A (https=)
WO (1) WO2020200900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2020035020A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020150626A1 (en) * 2019-01-18 2020-07-23 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2020200898A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020200899A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
CN109890829B (zh) * 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2020035020A1 (zh) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020150626A1 (en) * 2019-01-18 2020-07-23 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2020200898A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020200899A1 (en) * 2019-03-29 2020-10-08 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3947378B1 (en) 2024-11-13
MX2021011576A (es) 2021-10-13
CN113646305A (zh) 2021-11-12
SG11202110644WA (en) 2021-10-28
TW202102501A (zh) 2021-01-16
CO2021014223A2 (es) 2021-11-19
CA3134736A1 (en) 2020-10-08
IL286677A (en) 2021-10-31
MA55497A (fr) 2022-02-09
WO2020200900A1 (en) 2020-10-08
GB201904373D0 (en) 2019-05-15
EP3947378A1 (en) 2022-02-09
US20220218679A1 (en) 2022-07-14
AR118521A1 (es) 2021-10-20
PH12021552375A1 (en) 2022-09-19
AU2020252038A1 (en) 2021-11-25
BR112021019055A2 (pt) 2021-11-30
KR20210145238A (ko) 2021-12-01

Similar Documents

Publication Publication Date Title
JP2022526364A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP7326276B2 (ja) 新規化合物及び疾患の治療のためのその医薬組成物
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP2023536589A (ja) Ｍｔａｐ欠損及び／またはｍｔａ蓄積癌の治療に有用なピペリジン－１－イル－ｎ－ピリジン－３－イル－２－オキソアセトアミド誘導体
US20250019385A1 (en) Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2021527106A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
WO2018143315A1 (ja) キナゾリン化合物
EA028819B1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
CN113924146A (zh) 用于治疗疾病的新化合物及其药物组合物
JP2022526553A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP6153980B2 (ja) フェニルアミノピリミジン二環式化合物およびその使用
US10507201B2 (en) Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
JP2018530527A (ja) Ｅｚｈ２の阻害剤
KR20180118752A (ko) 섬유증의 치료를 위한 신규 화합물 및 그의 약학 조성물
TW202136271A (zh) 呋喃并吲唑衍生物
KR20150132170A (ko) 야누스 키나제 억제제로서의 비-시클릭 시아노에틸피라졸로 피리돈
JP2025504916A (ja) 化合物及び使用方法
JP2022526176A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
CA3211437A1 (en) Furoindazole derivatives as gpr84 antagonists
CN108137584A (zh) 作为irak抑制剂的6-[5-氨基-6-(2-乙氧基乙氧基)-咪唑并[4,5-b]吡啶-3-基]-烟腈衍生物及其用途
JP5916719B2 (ja) Ｊｎｋの阻害剤として有用な２−アミノ−ピリミジン誘導体
TW202502765A (zh) 一種prmt5抑制劑、其製備方法及應用
EA052682B1 (ru) Производные пиперидин-1-ил-n-пиридин-3-ил-2-оксоацетамида, пригодные для лечения раковых заболеваний с дефицитом мтар и/или с накоплением мта

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203